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Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease
in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate
binder, versus lanthanum carbonate (La) and sevelamer carbonate (Se), on serum FGF23, phosphorus, calcium, and intact
parathyroid hormone (iPTH) concentrations, and the development of vascular calcification in adenine-induced chronic renal
failure (CRF) rats. After induction of CRF, renal function was significantly impaired in all groups: uremic rats developed severe
hyperphosphatemia, and serum iPTH increased significantly. All uremic rats (except controls) then received phosphate binders
for 4 weeks. Hyperphosphatemia and increased serum iPTH were controlled to a similar extent in all phosphate binder-treatment
groups. Only sucroferric oxyhydroxide was associated with significantly decreased FGF23. Vascular calcifications of the thoracic
aorta were decreased by all three phosphate binders. Calcifications were better prevented at the superior part of the thoracic and
abdominal aorta in the PA21 treated rats. In adenine-induced CRF rats, sucroferric oxyhydroxide was as effective as La and Se
in controlling hyperphosphatemia, secondary hyperparathyroidism, and vascular calcifications. The role of FGF23 in calcification
remains to be confirmed.
1. Introduction
Cardiovascular disease (CVD) is a major cause of mortality
in patients with chronic kidney disease (CKD) [1]. Sev-
eral factors were identified in this process; elevated serum
phosphorus and FGF23 levels in particular are recognized
to be associated with CVD in patients with CKD [2–5].
Current therapy focuses on decreasing serum phosphorus
levels in CKD using phosphate binders and nutritional
consulting. Sucroferric oxyhydroxide (PA21) is a new iron
(III)-oxyhydroxide containing compound in which addition
of carbohydrates prevents iron oxyhydroxide from aging and
maintains its phosphate-binding capacity [6, 7].
FGF23 is a phosphaturic hormone that has an important
role in phosphate homeostasis [8]. FGF23 is produced by
osteocytes and directly affects the kidney by downregulating
the production of 1,25-vitamin D3 and the expression of
2a and 2c sodium-phosphate cotransporters in response to
phosphate overload [9]. FGF23 secretion frombone increases
as renal function declines. Phosphate retention occurs early
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in the course of renal failure. FGF23 increases urinary phos-
phate excretion and can be viewed as an adaptive response to
an elevated phosphate load.High FGF-23 levels are associated
with death and cardiovascular events in subjects with CKD
[10]. To date, there is little information on the effects of
phosphorus lowering by pharmacologic means on plasma
FGF23 levels. Abnormalities in mineral metabolism also
appear early in the course of CKD and result in clinically
relevant consequences such as vascular calcification. It has
recently been established that levels of FGF23 are increased
in early CKD [11].
We have previously shown that sucroferric oxyhydroxide
(PA21) is as effective as calcium carbonate, the traditional
phosphate binder, for controlling serum phosphorus levels,
and is superior in preventing the development of vascular
calcifications in uremic rats [12]. The aim of this study was
to compare the effects of sucroferric oxyhydroxide (PA21)
with two other noncalcium phosphate binders, lanthanum
carbonate and sevelamer carbonate, on concentrations of
serum FGF23, phosphorus, calcium, and intact parathyroid
hormone (iPTH), and in particular to investigate its potential
effect on the development of vascular calcifications in an
adenine-induced CKD model in rats.
2. Methods
2.1. Experimental Design. Theprocedures for the care and use
of experimental animals and the protocols were submitted to
and accepted by the local veterinary authorities, University
of Lausanne. Male Wistar rats (Charles River Laboratories,
L’Arbresle, France) were housed (3 rats/cage) in polycarbon-
ate cages in a pathogen-free, temperature-controlled (25∘C)
facility with a strict 12-hour light/dark cycle.The rats had free
access to chow diet and water [12].
As previously described, to induce chronic renal failure
(CRF), 10-week-old rats were fed a diet containing 0.75%
adenine and a high phosphorus content (1.3% phosphorus,
1.06% calcium, 1000 IU/kg vitamin D3, and 23% protein)
(Kliba Nafag 3200, Provimi Kliba AG, Kaiseraugst, Switzer-
land, supplemented with phosphorus and calcium) for 4
weeks [12]. After this time, adenine was withdrawn from the
high-phosphorus diet and blood sampling was performed at
the tail vein [12].
To compare the effects of the phosphate binders, the
same concentration (1% in the diet) of metal or resin, respec-
tively, was applied for each phosphate binder: 5% sucroferric
oxyhydroxide (PA21) was used to match with 1% iron, 2%
lanthanum carbonate to match with 1% lanthanum, and 1.5%
Renvela tomatchwith 1% of sevelamer carbonate.Themixing
of the binder with the diet was a two-step process: firstly, a dry
mixture was prepared and stored protected from air and light;
secondly, it was hydrated with the same volume of water and
homogenized before offering the diet to the animals [12].
The uremic rats were randomly assigned to one of the
following four CRF groups: (1) a control group, untreated
throughout the experiments (𝑛 = 22); (2) a group treatedwith
sucroferric oxyhydroxide (PA21) at 5% (CRF PA21; 𝑛 = 20);
(3) a group treated with lanthanum carbonate at 2% (CRF La;
𝑛 = 20); and (4) a group treated with sevelamer carbonate at
1.5% (CRF Se; 𝑛 = 20).
At sacrifice, after 4weeks of treatment, bloodwas sampled
by cardiac puncture for determination of serum calcium,
phosphorus, creatinine, alkaline phosphatase, iPTH, hema-
tocrit, and ferritin [12]. In addition, urine spot collection was
performed at sacrifice for all rats. After blood sampling, ani-
mals were euthanized and perfusedwith formalin.Thereafter,
aorta, carotid, and femoral arteries were harvested.
2.2. Phosphate Binders. Sucroferric oxyhydroxide (PA21), lot
097101A11, was provided by Vifor (International) Inc., St.
Gallen, Switzerland. Lanthanum(III) carbonate hydrate, lot
C16W033, was purchased from Alfa Aesar GmbH & Co,
Karlsruhe, Germany, and sevelamer carbonate (Renvela), lot
D0020B01, was from Genzyme, Naarden, The Netherlands.
2.3. Biochemical Analyses. Serum and urine creatinine, cal-
cium and phosphorus, and alkaline phosphatase concentra-
tions were measured using standard colorimetric method
(Cobas Mira, Roche, Basel, Switzerland). Serum iPTH and
ferritin were measured using commercial ELISA kits specific
for the full-length bioactive rat 1–84 iPTH and for rat
ferritin (both kits fromAlpcoDiagnostics, Salem, NH, USA).
FGF23 was assessed using a commercial full-length ELISA
kit specific for rat FGF23 (Millipore; Billerica, MA, USA).
Hematocrit was measured in triplicate immediately at the
time of sacrifice, using microfuge centrifugation (3min at
12,000 rpm) of a small blood droplet within a glass capillary.
2.4. Calcification Measurements. The carotid arteries, as well
as abdominal and thoracic aorta, were removed, fixed in
neutral buffered formalin, and cut into rings embedded
upright in the same paraffin block. Sections (4 𝜇m thickness)
were stained using von Kossa’s method [12–15]. Vascular
calcifications were evaluated histomorphometrically at a
magnification of 40x and were assessed in a blinded manner
on random sections of aorta. Morphologic image-processing
algorithmswere used for computer-assisted automated quan-
titative measurement of calcification from vessel sections
(Leika image-analysis software), revealed by the von Kossa’s
silver nitrate staining. Data were expressed as the relative
proportion (%) of calcified area (𝐶) of the aorta media to
total surface area (𝑇) of each ring (𝐶/𝑇). To avoid any
misinterpretation, the aorta rings were evaluated only if the
entire surface of the ring was present.
2.5. Statistical Analysis. Results are expressed as mean ±
SEM. Data derived from the different experimental groups
were compared using one-way analysis of variance and the
Bonferroni post hoc test, with the exception of the FGF23
data (which do not follow a Gaussian distribution), for which
the median and range are reported; a nonparametric analysis
(Kruskal-Wallis test followed by Mann-Whitney post hoc
test) was used for this dataset. Chi-square analysis was used
to compare the data on vascular calcifications. A 𝑝 value of
<0.05 was considered significant, and all computations were
done using SPSS version 7.0 (SPSS, Inc, Chicago, IL, USA).
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Table 1: Serum biochemistry, prior to binder treatment.
CRF group/binder type 𝑁 Weightg
Creatinine
𝜇mol/L
Ca
mmol/L
P
mmol/L
CRF control 18 216 ± 4 251 ± 17.7 2.27 ± 0.40 4.83 ± 0.28
CRF PA21 19 217 ± 4 239 ± 19.0 2.44 ± 0.04 4.75 ± 0.32
CRF Se 20 211 ± 3 229 ± 16.2 2.42 ± 0.06 4.44 ± 0.23
CRF La 18 216 ± 4 233 ± 10.6 2.41 ± 0.03 4.62 ± 0.21
Ca, calcium; La, lanthanum carbonate; P, phosphorus; Se, sevelamer carbonate; PA21, sucroferric oxyhydroxide. Values shown are mean ± SE.
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Figure 1: Change in body weight during the study.
3. Results
3.1. Mortality. Of the total 82 CRF rats, seven had to be
euthanized 1 week after cessation of adenine feeding due to
malnutrition (weight < 160 g) and severe uremia (4/22 in the
control group, 1/20 in the sucroferric oxyhydroxide group,
and 2/20 in the lanthanum carbonate group).
3.2. Biochemical Analyses. After 4 weeks of adenine admin-
istration to induce renal failure, and before starting the
phosphate-binder treatment, mean body weight and con-
centrations of serum creatinine and calcium and phosphate
concentrations were similar in all CRF groups (Table 1).
There was no difference in body weight of CRF rats
between time of randomization and end of the study
(Figure 1).
Each animal was weighed weekly during the study.
Adeninewas started atWeek 0 for 4weeks; phosphate binders
were started at Week 4 for 4 weeks after withdrawal of
adenine. Rats were sacrificed on the first day ofWeek 8.There
was no statistical difference between the groups.
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Figure 2: Median serum FGF23 concentration after 4 weeks of
binder treatment.
After 4 weeks of phosphate-binder treatment, serum
creatinine concentrations and also body weights were similar
in all CRF groups (Table 2).
After 4 weeks of treatment with the three phosphate
binders, a significant reduction in serum phosphorus was
observed (Table 2). Serum calcium concentration was higher
in the uremic rats treated by sevelamer and lanthanum
carbonate. CRF control rats also developed marked hyper-
parathyroidism, as shown by elevated iPTH levels at time
of sacrifice (Table 2). iPTH was reduced to a similar extent
by the three phosphate binders (𝑝 < 0.05), while serum
alkaline phosphatase levelswere only slightly reduced in these
groups although the differencewas not statistically significant
(Table 2). Phosphaturia was dramatically decreased in all
three groups (𝑝 < 0.05) (Table 3). Hematocrit levels were
significantly lower in the sevelamer carbonate and lanthanum
carbonate groups compared with the CRF control group
(Table 2).
Uremia was associated with increased serum FGF23
concentration in the CRF control group. Serum FGF23
concentration were lower in all three groups treated with
phosphate-binders, but this was statistically significant only
in the case of sucroferric oxyhydroxide (PA21) (Figure 2).
The effect of sucroferric oxyhydroxide (PA21) and other
phosphate binder on FGF23 concentrations was evaluated
after 4 weeks of treatment. Serum FGF23 was decreased (𝑝 <
0.05) in animals in the CRF PA21 group (𝑛 = 19, median
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Figure 3: Vascular calcifications in carotid artery, abdominal aorta, and inferior and superior part of thoracic aorta in uremic controls and
phosphate-binder groups. ∗𝑝 < 0.05 versus CRF control, ∗∗𝑝 < 0.001 versus CRF control, and ∗∗∗𝑝 < 0.05 versus CRF La.
Table 3: Urinary values at sacrifice.
CRF group/binder
type 𝑁
Ca/creat. U
mmol/mmol
P/creat. U
mmol/mmol
CRF control 18 1.45 ± 0.17 17.8 ± 1.91
CRF PA21 16 1.12 ± 0.12 4.31 ± 0.61a
CRF Se 20 1.44 ± 0.12 10.1 ± 0.73a
CRF La 17 1.45 ± 0.12 7.88 ± 0.61a
Ca, calcium; La, lanthanum carbonate; P, phosphorus; Se, sevelamer carbon-
ate; PA21, sucroferric oxyhydroxide. a𝑝 < 0.05 versus CRF control. Values
shown are mean ± SE.
0.2 ng/mL, range 0.1–7.6), compared with the CRF control
group animals (𝑛 = 18, median, 0.7 ng/mL, range 0.1–9.7).
Serum FGF23 in the CRF PA21 group was also lower (𝑝 <
0.05) than in theCRFSe group (𝑛 = 19,median 0.4, range 0.1–
10.6). In contrast, there were no differences in serum FGF23
between the CRF control, Se, and La groups (La: 𝑛 = 19,
median 0.3 ng/mL, range 0.1–9.1).
3.3. Vascular Calcifications. Vascular calcifications were
observed inmore than 70% of the uremic control rats. Vascu-
lar calcifications were evaluated at different sites: (a) carotids,
(b) inferior and superior part of the thoracic aorta, and
(c) abdominal aorta. Vascular calcifications of the thoracic
aorta (inferior and superior part) were significantly decreased
in all three phosphate binder groups (Figures 3 and 4 and
Table 4). Vascular calcifications of the abdominal aorta were
only decreased in the sucroferric oxyhydroxide (PA21) group
and PA21 was more effective than lanthanum carbonate in
preventing calcifications in the superior part of the thoracic
aorta (Figures 3 and 4 and Table 4).
4. Discussion
This is the first study to compare sucroferric oxyhydroxide
with sevelamer carbonate and lanthanumcarbonate in an ani-
mal model. It demonstrates that sucroferric oxyhydroxide is
as effective as sevelamer carbonate and lanthanum carbonate
in decreasing serum phosphorus and iPTH concentrations
and reducing the progression of vascular calcifications.
The weight of the animals in all CRF groups decreased
during the 4 weeks of adenine administration and increased
after adenine was withdrawn. A body weight decrease in
adenine-induced CRF animals has been described in previ-
ous studies [12, 16] and is probably due to development of
uremia and absence of appetite during the administration of
adenine.
Based on the results of serum and urinary phosphorus
levels, sucroferric oxyhydroxide was shown to be equally as
effective in controlling hyperphosphatemia as sevelamer car-
bonate and lanthanum carbonate. Secondary hyperparathy-
roidism was similarly reduced by all three binders. Vascular
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Figure 4: vonKossa stains of the vascular calcifications of adenine fed rats after 4weeks of treatment. Vascular calcifications were evaluated by
von Kossa staining and histomorphometrically with a magnification of 40×. (a) Superior thoracic aorta, (b) carotid, and (c) abdominal aorta
from CRF control rats. (d) Superior thoracic aorta, (e) carotid, and (f) abdominal aorta from CRF rats treated by sucroferric oxyhydroxide
(PA21).
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Table 4: Impact of phosphate binder treatment on vascular calcifications of carotid artery, abdominal aorta, and inferior and superior part
of thoracic aorta.
Carotid Abdominal aorta Inferior thoracic aorta Superior thoracic aorta
CRF PA21 No Yes Yes Yes
CRF Se No No Yes Yes
CRF La No No Yes Yes
calcifications of thoracic aorta were significantly decreased
by the three phosphate binders to a similar extent by the
control of hyperphosphatemia and hyperparathyroidism [12,
17, 18]. Less calcification in the upper part of the tho-
racic aorta was observed in sucroferric oxyhydroxide-treated
animals than in those treated with lanthanum carbonate.
Several studies have reported that the risk of calcification
increases in the presence of hypercalcemia [19, 20]. The
absence of significant serum hypercalcemia concentration in
the sucroferric oxyhydroxide-treated animals could provide
a potential explanation for the reduced vascular calcifica-
tion. London et al. have suggested that the hypercalcemia
associated with higher calcium phosphate product levels
may worsen cardiovascular events in the uremic population,
through a progressive increase in calcium deposition in the
coronary arteries and heart valves [19]. More recently, in a
study including 384 dialysis patients, Noordzij et al. reported
that hypercalcemia and hyperparathyroidismwere associated
with an increased risk of progression of vascular calcifications
[20]. Additional influences, such as hemodynamic factors
relating to specific anatomic sites of aorta, could lead to
a differential progression of atherosclerosis and intima-
media calcification [21–23]. In this study we did not include
measurement of hemodynamic parameters and thus cannot
address a potential contribution of differences in hemody-
namics. Interestingly, the vascular calcifications of the aorta
differed, in regard to their anatomical position. Some studies
demonstrate a high level of vascular calcification in this
adenine uremic rat model [24–26]; vascular calcifications
were presents in 70% of uremic control rats in our study.
Conversely, Neven et al. have reported that only 50% of
uremic rats developed vascular calcifications [16]. These
differences could be explained by relative differences between
the studies concerning the concentration and the duration of
the adenine, the adjunction of vitamin D, and the calcium
and phosphorus concentration of the diet which influence
the degree of calcifications and point the difficulties to obtain
the adequate uremic animal model of vascular calcifications.
More recently, a low protein diet or the administration of
warfarin seems to increase the rate of vascular calcifications.
Warfarin inhibits matrix Gla protein, a vitamin K-dependent
protein that counteracts artery calcification [27].
High FGF23 levels are associated with death and cardio-
vascular events in CKDpatients [28] andmay be explained by
the direct effect of FGF23 on the heart, which was reported
by Faul et al. [3]. In the early stages of CKD, circulating
FGF23 levels increase with declining renal function as a
physiological compensation to stabilize serum phosphorus
levels [29, 30]. Results from some clinical studies sug-
gest there is an association between elevated FGF23 and
vascular calcification [31]. Recently, it was also shown that
FGF23 enhanced phosphate-induced calcification in Klotho-
overexpressing vascular smooth muscle cells and increased
osteoblastic marker expression [32]. However, conflicting
results have been reported in the literature. The relationship
between FGF23 and vascular calcification remains a matter
of debate [33]. In one study, high serum levels of FGF23
were reported to be associated with more severe vascular
calcification in CKD patients [34], while another study
involving non-CKD patients observed a negative association
between FGF-23 and the presence of atherosclerotic lesions
[35]. Most (though not all) recent studies have demonstrated
an involvement of both Klotho and FGF23 in vascular calci-
fications, via their interaction or through separate individual
effects [33, 36].Their precise roles in vascular calcificationwill
require further study.
Our results confirmed results of in vitro and preclinical
investigations that sucroferric oxyhydroxide is an effective
phosphate binder. Serum phosphorus and iPTH decreased
rapidly with the three noncalcium phosphate binders. But,
this is the first study witch evaluated the effect of sucroferric
oxyhydroxide on vascular calcifications compared with lan-
thanum carbonate or sevelamer carbonate. The three binders
had a positive influence of the progression of the vascular
calcification. Interestingly, a slightly greater effect on the
superior part of thoracic aorta was observed with sucrofer-
ric oxyhydroxide, compared with the other two phosphate
binders. One could speculate that, after a longer period
of treatment, lanthanum carbonate or sevelamer carbonate
might also similarly affect the level of FGF23. In a previous
study, we demonstrated that, in comparison with sucroferric
oxyhydroxide, the traditional calcium carbonate phosphate
binder decreased iPTH and phosphorus concentration but
not FGF23 levels. We also showed that, at the same time,
vascular calcifications were less well prevented by calcium
carbonate, in comparisonwith sucroferric oxyhydroxide [12].
For other noncalciumphosphate binders, the results reported
in the literature are conflicting, with respect to variation of
serum FGF23 levels. Maizel et al. reported that sevelamer
hydrochloride improved aortic systolic expansion rate, pulse-
wave velocity, and diastolic function, but serum FGF23 levels
were reduced after 14 weeks of treatment [37]. In contrast, in a
different animalmodel, Nagano et al. reported that sevelamer
effectively inhibited the increase in serum FGF23 and PTH
while calcification was not evaluated [38]. In contrast to
previous studies in normophosphatemic subjects, one study
attempted to investigate whether sevelamer carbonate could
lower FGF23 levels in patients with CKD (Stages 3–5)
and hyperphosphatemia [39]. Although serum phosphorus
reduction was achieved, no significant reduction in plasma
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FGF23 levels was seen. The novel aspect of the study was
that FGF23 was reduced as early as three months and did
not require prolonged therapy. Our study provides the first
data on sucroferric oxyhydroxide and FGF23 in rats. Further
studies are needed to show whether an early decrease of
FGF23 by sucroferric oxyhydroxide can predict a slower
progression of vascular calcification in CKD.
5. Conclusions
Administration of sucroferric oxyhydroxide, a new iron-
based noncalcium phosphate binder, to rats with adenine-
induced CRF was found to be as effective in controlling
hyperphosphatemia, secondary hyperparathyroidism, and
vascular calcification as sevelamer and lanthanum carbonate.
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